The Irish Pharmaceutical Healthcare Association (IPHA), which represents the research-based pharmaceutical industry in Ireland, has said a continued focus on innovation is key to unlocking the potential of new medicines to improve healthcare outcomes and attract investments in the future.
IPHA’s statement comes as proposed legislation, unveiled by the Commission today [Monday], seeks to introduce a Special Protection Certificate (SPC) manufacturing waiver. The SPCs allow pharmaceutical companies that manufacture innovative medicines in the EU to extend patent periods to compensate for lengthy clinical trials development times needed to ensure new medicines are safe and effective.
IPHA believes the proposed laws on intellectual property would be a setback for an industry centred on innovation when the focus should remain on creating the best conditions required for the discovery and delivery of new medicines and the attraction of fresh investments to Ireland.
According to IPHA Chief Executive Oliver O’Connor: “It is critical that policy for the biopharma industry remains focused on innovation as the key to unlocking the potential of new medicines to improve healthcare outcomes and generate more high-quality jobs for Ireland.
“Future investments, and the capacity of the industry to continue scaling and creating jobs, are underpinned by a commitment to innovation and intellectual property rights. Patients rely on industry innovation for the discovery and delivery of new medicines. We must guard against any moves, including the proposed introduction of manufacturing waivers, that could weaken our ability to support the work of the originator companies in the biopharma sector.”
The Irish Pharmaceutical Healthcare Association (IPHA) represents the international research based pharmaceutical industry in Ireland. Our members include both manufacturers of prescription medicines and non-prescription or consumer health care medicines.
For information contact Philip Hannon on 087 2870891